Browse > Article
http://dx.doi.org/10.3904/kjm.2012.83.3.405

Imatinib Mesylate is Effective for Patients Not Only with Chronic Myeloid Leukemia, but Also Rheumatoid Arthritis  

Jung, Hyun-Jun (Department of Internal Medicine, Kyung Hee University School of Medicine, Kyung Hee University Hospital at Gangdong)
Kim, Dae-Ho (Department of Internal Medicine, Kyung Hee University School of Medicine, Kyung Hee University Hospital at Gangdong)
Song, Ran (Department of Internal Medicine, Kyung Hee University School of Medicine, Kyung Hee University Hospital at Gangdong)
Hong, Seung-Jae (Department of Internal Medicine, Kyung Hee University School of Medicine, Kyung Hee University Medical Center)
Yang, Hyung-In (Department of Internal Medicine, Kyung Hee University School of Medicine, Kyung Hee University Hospital at Gangdong)
Eo,Wan-Kyu (Department of Internal Medicine, Kyung Hee University School of Medicine, Kyung Hee University Hospital at Gangdong)
Lee, Sang-Hoon (Department of Internal Medicine, Kyung Hee University School of Medicine, Kyung Hee University Hospital at Gangdong)
Publication Information
The Korean Journal of Medicine / v.83, no.3, 2012 , pp. 405-410 More about this Journal
Abstract
Synovial tissue proliferation and inflammation are regarded as possible causes of rheumatoid arthritis. Activation of tyrosine kinase by numerous cytokines and BCR-ABL translocation contribute to synovial tissue inflammation and the development of rheumatoid arthritis, respectively. Imatinib is a tyrosine kinase-blocking agent that is widely used for treating chronic myeloid leukemia. We found several interesting case reports of patients with refractory rheumatoid arthritis who entered remission after initiating imatinib therapy. However, only one case report on treating rheumatoid arthritis with imatinib was found in Korea. Here, we describe the case of a 50-year-old man who showed clinical remission of rheumatoid arthritis and chronic myeloid leukemia after receiving 3 months of imatinib therapy.
Keywords
Chronic myelogenous leukemia; Imatinib; Rheumatoid arthritis;
Citations & Related Records
연도 인용수 순위
  • Reference
1 Miyachi K, Ihara A, Hankins RW, Murai R, Maehiro S, Miyashita H. Efficacy of imatinib mesylate (STI571) treatment for a patient with rheumatoid arthritis developing chronic myelogenous leukemia. Clin Rheumatol 2003;22: 329-332.   DOI   ScienceOn
2 Takeuchi T, Abe T. Tyrosine phosphorylated proteins in synovial cells of rheumatoid arthritis. Int Rev Immunol 1998;17:365-381.   DOI
3 Eklund KK. Mast cells in the pathogenesis of rheumatic diseases and as potential targets for anti-rheumatic therapy. Immunol Rev 2007;217:38-52.   DOI   ScienceOn
4 Pereira I, Fialho S, Castro G, Zimmermann A. Imatinib mesylate induces clinical remission in rheumatoid arthritis. Joint Bone Spine 2010;77:372-373.   DOI   ScienceOn
5 Jeon HK, Park YE, Kim SI, et al. Efficacy of imatinib mesylate treatment for a patient with rheumatoid arthritis and who developed chronic myelogenous leukemia. J Rheum Dis 2011;18:118-121.   DOI
6 National Cancer Information Center. Cancer Definition [Internet]. Seoul (KR): National Cancer Information Center, c2012 [cited 2012 Feb 15]. Available from: http://www.cancer.go.kr/ncic/cics_b/ 01/012/1253431_5872.html.
7 Buchdunger E, Cioffi CL, Law N, et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther 2000;295:139-145.
8 Askling J, Fored CM, Baecklund E, et al. Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists. Ann Rheum Dis 2005;64:1414-1420.   DOI   ScienceOn
9 Thomas E, Brewster DH, Black RJ, Macfarlane GJ. Risk of malignancy among patients with rheumatic conditions. Int J Cancer 2000;88:497-502.   DOI   ScienceOn
10 Senel S, Kaya E, Aydogdu I, Erkurt MA, Kuku I. Rheumatic diseases and chronic myelogenous leukemia, presentation of four cases and review of the literature. Rheumatol Int 2006;26:857-861.   DOI   ScienceOn